{"transactions":[{"id":675908,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-08-25T20:43:22.000Z","date":"2026-08-21","kind":"sale","planned":false,"acquired":false,"shares":29697,"price":2.12,"value":62957.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects forfeiture of 54,479 shares subject to performance RSUs granted to the Reporting Person on August 14, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 7,495 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program."}],"balance_after":488267,"source":{"system":"sec-edgar","filing":"0001628280-26-058920","document":"wk-form4_1787690594.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000162828026058920/wk-form4_1787690594.xml","form_type":"4"}},{"id":715458,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2026-07-06T21:51:21.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":476190,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the stock option shall vest on July 1, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":476190,"derivative":{"exercise_price":2.11,"expiration_date":"2036-07-01","underlying":"Common Stock","underlying_shares":476190},"source":{"system":"sec-edgar","filing":"0001851044-26-000005","document":"wk-form4_1783374679.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000185104426000005/wk-form4_1783374679.xml","form_type":"4"}},{"id":715457,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-07-06T21:51:21.000Z","date":"2026-07-01","kind":"grant","planned":false,"acquired":true,"shares":134530,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from July 20, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from July 20, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from July 20, 2026, subject to continued service through the vesting date."}],"balance_after":134530,"derivative":{"underlying":"Common Stock","underlying_shares":134530},"source":{"system":"sec-edgar","filing":"0001851044-26-000005","document":"wk-form4_1783374679.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000185104426000005/wk-form4_1783374679.xml","form_type":"4"}},{"id":728764,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:35:15.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001221355-26-000002","document":"wk-form4_1782246909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135526000002/wk-form4_1782246909.xml","form_type":"4"}},{"id":728763,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:35:15.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":false,"shares":47700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":47700},"source":{"system":"sec-edgar","filing":"0001221355-26-000002","document":"wk-form4_1782246909.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135526000002/wk-form4_1782246909.xml","form_type":"4"}},{"id":728762,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-23T20:35:15.000Z","date":"2026-06-18","kind":"exercise","planned":false,"acquired":true,"shares":47700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":398463,"source":{"system":"sec-edgar","filing":"0001221355-26-000002","document":"wk-form4_1782246909.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135526000002/wk-form4_1782246909.xml","form_type":"4"}},{"id":728564,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":29667,"kind":"person","name":"MESSEMER DEBORAH M.","position":1,"cik":"0001754424","reported_name":"MESSEMER DEBORAH M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:34:12.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001737287-26-000021","document":"wk-form4_1782246849.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728726000021/wk-form4_1782246849.xml","form_type":"4"}},{"id":728556,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":10744,"kind":"person","name":"Mayo Stephen","position":1,"cik":"0001849061","reported_name":"Mayo Stephen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-06-23T20:33:05.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":144400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments."}],"balance_after":144400,"derivative":{"exercise_price":2,"expiration_date":"2036-06-18","underlying":"Common Stock","underlying_shares":144400},"source":{"system":"sec-edgar","filing":"0001737287-26-000019","document":"wk-form4_1782246783.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728726000019/wk-form4_1782246783.xml","form_type":"4"}},{"id":728745,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:32:02.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal\nsemi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001197020-26-000002","document":"wk-form4_1782246720.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000119702026000002/wk-form4_1782246720.xml","form_type":"4"}},{"id":728567,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:29:59.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001700969-26-000002","document":"wk-form4_1782246596.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000170096926000002/wk-form4_1782246596.xml","form_type":"4"}},{"id":728667,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15984,"kind":"person","name":"Humer Franz B","position":1,"cik":"0001548072","reported_name":"Humer Franz B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:28:07.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001548072-26-000002","document":"wk-form4_1782246485.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1548072/000154807226000002/wk-form4_1782246485.xml","form_type":"4"}},{"id":728555,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35887,"kind":"person","name":"Barrett Elizabeth A.","position":1,"cik":"0001764157","reported_name":"Barrett Elizabeth A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-06-23T20:26:45.000Z","date":"2026-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001764157-26-000004","document":"wk-form4_1782246402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000176415726000004/wk-form4_1782246402.xml","form_type":"4"}},{"id":801625,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":51454,"kind":"person","name":"Yoshiyama Annie","position":1,"cik":"0001835208","reported_name":"Yoshiyama Annie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-04-23T20:16:11.000Z","date":"2026-04-21","kind":"sale","planned":false,"acquired":false,"shares":9586,"price":2.31,"value":22143.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.31 to $2.33, inclusive. The reporting person undertakes to provide the\nIssuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range\nset forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 3,781 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program."}],"balance_after":124517,"source":{"system":"sec-edgar","filing":"0001835208-26-000003","document":"wk-form4_1776975369.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000183520826000003/wk-form4_1776975369.xml","form_type":"4"}},{"id":820439,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-04-02T20:47:39.000Z","date":"2026-03-31","kind":"sale","planned":false,"acquired":false,"shares":2867,"price":2.5,"value":7167.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":195338,"source":{"system":"sec-edgar","filing":"0002057918-26-000007","document":"wk-form4_1775162856.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000205791826000007/wk-form4_1775162856.xml","form_type":"4"}},{"id":835452,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-18T20:06:54.000Z","date":"2026-03-16","kind":"sale","planned":false,"acquired":false,"shares":4835,"price":2.47,"value":11942.45,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.46 to $2.47, inclusive. The reporting person undertakes to\nprovide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price\nwithin the range set forth above."}],"balance_after":198205,"source":{"system":"sec-edgar","filing":"0001737287-26-000015","document":"wk-form4_1773864406.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000173728726000015/wk-form4_1773864406.xml","form_type":"4"}},{"id":834495,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-03-18T20:05:48.000Z","date":"2026-03-16","kind":"sale","planned":false,"acquired":false,"shares":47763,"price":2.47,"value":117974.61,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program."}],"balance_after":5150599,"source":{"system":"sec-edgar","filing":"0001737287-26-000013","document":"wk-form4_1773864344.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728726000013/wk-form4_1773864344.xml","form_type":"4"}},{"id":862393,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-03-04T22:42:16.000Z","date":"2026-03-02","kind":"sale","planned":false,"acquired":false,"shares":7132,"price":2.6,"value":18543.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.60 to $2.67, inclusive. The reporting person undertakes to\nprovide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price\nwithin the range set forth above."}],"balance_after":203040,"source":{"system":"sec-edgar","filing":"0002057918-26-000003","document":"wk-form4_1772664133.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000205791826000003/wk-form4_1772664133.xml","form_type":"4"}},{"id":919754,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:20:22.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":105720,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":105720,"derivative":{"underlying":"Common Stock","underlying_shares":105720},"source":{"system":"sec-edgar","filing":"0001737287-26-000011","document":"wk-form4_1770243619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000173728726000011/wk-form4_1770243619.xml","form_type":"4"}},{"id":919753,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:20:22.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":373757,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":373757,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":373757},"source":{"system":"sec-edgar","filing":"0001737287-26-000011","document":"wk-form4_1770243619.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000173728726000011/wk-form4_1770243619.xml","form_type":"4"}},{"id":919752,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2026-02-04T22:20:22.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":7549,"price":1.73,"value":13059.77,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.75, inclusive. The reporting person undertakes to\nprovide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price\nwithin the range set forth above."}],"balance_after":210172,"source":{"system":"sec-edgar","filing":"0001737287-26-000011","document":"wk-form4_1770243619.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000173728726000011/wk-form4_1770243619.xml","form_type":"4"}},{"id":919032,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:18:18.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":392586,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F8","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":392586,"derivative":{"underlying":"Common Stock","underlying_shares":392586},"source":{"system":"sec-edgar","filing":"0001737287-26-000009","document":"wk-form4_1770243495.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728726000009/wk-form4_1770243495.xml","form_type":"4"}},{"id":919031,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:18:18.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":1387931,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1387931,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":1387931},"source":{"system":"sec-edgar","filing":"0001737287-26-000009","document":"wk-form4_1770243495.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728726000009/wk-form4_1770243495.xml","form_type":"4"}},{"id":919030,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2026-02-04T22:18:18.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":95269,"price":1.8,"value":171484.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.87, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,562 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program."}],"balance_after":5185862,"source":{"system":"sec-edgar","filing":"0001737287-26-000009","document":"wk-form4_1770243495.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728726000009/wk-form4_1770243495.xml","form_type":"4"}},{"id":919354,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:16:19.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":152480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":152480,"derivative":{"underlying":"Common Stock","underlying_shares":152480},"source":{"system":"sec-edgar","filing":"0001737287-26-000007","document":"wk-form4_1770243376.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000173728726000007/wk-form4_1770243376.xml","form_type":"4"}},{"id":919353,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:16:19.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":539072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":539072,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":539072},"source":{"system":"sec-edgar","filing":"0001737287-26-000007","document":"wk-form4_1770243376.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000173728726000007/wk-form4_1770243376.xml","form_type":"4"}},{"id":919352,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2026-02-04T22:16:19.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":24001,"price":1.76,"value":42241.76,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.83, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":1252795,"source":{"system":"sec-edgar","filing":"0001737287-26-000007","document":"wk-form4_1770243376.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000173728726000007/wk-form4_1770243376.xml","form_type":"4"}},{"id":919169,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:12:18.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":152480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":152480,"derivative":{"underlying":"Common Stock","underlying_shares":152480},"source":{"system":"sec-edgar","filing":"0001362155-26-000002","document":"wk-form4_1770243135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000136215526000002/wk-form4_1770243135.xml","form_type":"4"}},{"id":919168,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:12:18.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":539072,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":539072,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":539072},"source":{"system":"sec-edgar","filing":"0001362155-26-000002","document":"wk-form4_1770243135.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000136215526000002/wk-form4_1770243135.xml","form_type":"4"}},{"id":919167,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2026-02-04T22:12:18.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":22900,"price":1.76,"value":40304.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.82, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":564948,"source":{"system":"sec-edgar","filing":"0001362155-26-000002","document":"wk-form4_1770243135.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000136215526000002/wk-form4_1770243135.xml","form_type":"4"}},{"id":918946,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":51454,"kind":"person","name":"Yoshiyama Annie","position":1,"cik":"0001835208","reported_name":"Yoshiyama Annie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:09:39.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":50827,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":50827,"derivative":{"underlying":"Common Stock","underlying_shares":50827},"source":{"system":"sec-edgar","filing":"0001737287-26-000005","document":"wk-form4_1770242977.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728726000005/wk-form4_1770242977.xml","form_type":"4"}},{"id":918945,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":51454,"kind":"person","name":"Yoshiyama Annie","position":1,"cik":"0001835208","reported_name":"Yoshiyama Annie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:09:39.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":179691,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":179691,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":179691},"source":{"system":"sec-edgar","filing":"0001737287-26-000005","document":"wk-form4_1770242977.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728726000005/wk-form4_1770242977.xml","form_type":"4"}},{"id":918944,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":51454,"kind":"person","name":"Yoshiyama Annie","position":1,"cik":"0001835208","reported_name":"Yoshiyama Annie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2026-02-04T22:09:39.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":4167,"price":1.72,"value":7167.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.74, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 3,826 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program."}],"balance_after":130322,"source":{"system":"sec-edgar","filing":"0001737287-26-000005","document":"wk-form4_1770242977.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728726000005/wk-form4_1770242977.xml","form_type":"4"}},{"id":919570,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of R&D"}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:07:38.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":203307,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":203307,"derivative":{"underlying":"Common Stock","underlying_shares":203307},"source":{"system":"sec-edgar","filing":"0001737287-26-000002","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000173728726000002/wk-form4_1770242855.xml","form_type":"4"}},{"id":919569,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of R&D"}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:07:38.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":718763,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":718763,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":718763},"source":{"system":"sec-edgar","filing":"0001737287-26-000002","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000173728726000002/wk-form4_1770242855.xml","form_type":"4"}},{"id":919568,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of R&D"}}],"security":"Common Stock","published_at":"2026-02-04T22:07:38.000Z","date":"2026-02-02","kind":"sale","planned":false,"acquired":false,"shares":35700,"price":1.77,"value":63189.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.87, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":581166,"source":{"system":"sec-edgar","filing":"0001737287-26-000002","document":"wk-form4_1770242855.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000173728726000002/wk-form4_1770242855.xml","form_type":"4"}},{"id":919253,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-02-04T22:04:12.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":263033,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F6","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal\nannual installments over the four-year period from February 2, 2026, subject to continued service through the vesting date."}],"balance_after":263033,"derivative":{"underlying":"Common Stock","underlying_shares":263033},"source":{"system":"sec-edgar","filing":"0001296549-26-000002","document":"wk-form4_1770242650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000129654926000002/wk-form4_1770242650.xml","form_type":"4"}},{"id":919252,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2026-02-04T22:04:12.000Z","date":"2026-02-02","kind":"grant","planned":false,"acquired":true,"shares":929913,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":929913,"derivative":{"exercise_price":1.87,"expiration_date":"2036-02-02","underlying":"Common Stock","underlying_shares":929913},"source":{"system":"sec-edgar","filing":"0001296549-26-000002","document":"wk-form4_1770242650.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000129654926000002/wk-form4_1770242650.xml","form_type":"4"}},{"id":932428,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of R&D"}}],"security":"Common Stock","published_at":"2026-01-23T21:15:10.000Z","date":"2026-01-21","kind":"sale","planned":false,"acquired":false,"shares":26269,"price":1.56,"value":40979.64,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":616866,"source":{"system":"sec-edgar","filing":"0001851044-26-000003","document":"wk-form4_1769202908.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000185104426000003/wk-form4_1769202908.xml","form_type":"4"}},{"id":960801,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-12-22T23:57:11.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":false,"shares":47700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"On June 23, 2025, this grant was erroneously reported as 94,500 shares and is corrected here upon the vesting of the first of the semi-annual installments."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2018 Plan."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":47700,"derivative":{"underlying":"Common Stock","underlying_shares":47700},"source":{"system":"sec-edgar","filing":"0001221355-25-000005","document":"wk-form4_1766447828.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135525000005/wk-form4_1766447828.xml","form_type":"4"}},{"id":960800,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-12-22T23:57:11.000Z","date":"2025-12-18","kind":"exercise","planned":false,"acquired":true,"shares":47700,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":350763,"source":{"system":"sec-edgar","filing":"0001221355-25-000005","document":"wk-form4_1766447828.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000122135525000005/wk-form4_1766447828.xml","form_type":"4"}},{"id":994244,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-11-19T21:09:26.000Z","date":"2025-11-17","kind":"sale","planned":false,"acquired":false,"shares":786,"price":1.22,"value":958.92,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.22 to $1.23, inclusive. The reporting person undertakes to\nprovide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price\nwithin the range set forth above."}],"balance_after":217721,"source":{"system":"sec-edgar","filing":"0001737287-25-000094","document":"wk-form4_1763586562.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000173728725000094/wk-form4_1763586562.xml","form_type":"4"}},{"id":1014218,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-10-23T22:20:44.000Z","date":"2025-10-21","kind":"sale","planned":false,"acquired":false,"shares":36744,"price":1.2565,"value":46168.836,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Pursuant to an employee stock purchase program, includes 6,000 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 and 6,000 shares of the Issuer's common stock acquired by the reporting person on September 15,2025."}],"balance_after":1276796,"source":{"system":"sec-edgar","filing":"0001737287-25-000091","document":"wk-form4_1761258041.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000173728725000091/wk-form4_1761258041.xml","form_type":"4"}},{"id":1103567,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2025-06-24T01:04:04.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":144400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments."}],"balance_after":144400,"derivative":{"exercise_price":1.29,"expiration_date":"2035-06-18","underlying":"Common Stock","underlying_shares":144400},"source":{"system":"sec-edgar","filing":"0001737287-25-000077","document":"wk-form4_1750727037.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000173728725000077/wk-form4_1750727037.xml","form_type":"4"}},{"id":1103410,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":29667,"kind":"person","name":"MESSEMER DEBORAH M.","position":1,"cik":"0001754424","reported_name":"MESSEMER DEBORAH M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-24T01:03:53.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Messemer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Messemer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Messemer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001737287-25-000076","document":"wk-form4_1750727027.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000076/wk-form4_1750727027.xml","form_type":"4"}},{"id":1103503,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15984,"kind":"person","name":"Humer Franz B","position":1,"cik":"0001548072","reported_name":"Humer Franz B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-24T01:03:43.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Humer has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001737287-25-000075","document":"wk-form4_1750727017.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1548072/000173728725000075/wk-form4_1750727017.xml","form_type":"4"}},{"id":1103409,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35887,"kind":"person","name":"Barrett Elizabeth A.","position":1,"cik":"0001764157","reported_name":"Barrett Elizabeth A.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-24T01:03:34.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Ms. Barrett has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001737287-25-000074","document":"wk-form4_1750727007.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000074/wk-form4_1750727007.xml","form_type":"4"}},{"id":1103408,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":10744,"kind":"person","name":"Mayo Stephen","position":1,"cik":"0001849061","reported_name":"Mayo Stephen","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-24T01:03:22.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Mayo has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Mayo has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. Mr. Mayo has elected to defer the receipt of Common Stock upon the vesting of her RSUs pursuant to the Companys Non-Employee Director Compensation Policy until the earlier of (i) 30 days following separation from the Board or (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001737287-25-000073","document":"wk-form4_1750726995.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000073/wk-form4_1750726995.xml","form_type":"4"}},{"id":1103421,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-24T01:03:12.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":95400,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Company Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date. The reporting person has elected to defer the receipt of Common Stock upon the vesting of their RSUs pursuant to the Company's Non-Employee Director Compensation Policy until earlier of (i)  30 days following separation from continuous service with the company and (ii) a change in control of the Company."}],"balance_after":95400,"derivative":{"underlying":"Common Stock","underlying_shares":95400},"source":{"system":"sec-edgar","filing":"0001737287-25-000072","document":"wk-form4_1750726985.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000173728725000072/wk-form4_1750726985.xml","form_type":"4"}},{"id":1103579,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2025-06-24T01:03:01.000Z","date":"2025-06-18","kind":"grant","planned":false,"acquired":true,"shares":94500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in two successive equal semi-annual installments over the one-year period measured from the date of grant, subject to continued service through the vesting date."}],"balance_after":94500,"derivative":{"underlying":"Common Stock","underlying_shares":94500},"source":{"system":"sec-edgar","filing":"0001737287-25-000071","document":"wk-form4_1750726975.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000173728725000071/wk-form4_1750726975.xml","form_type":"4"}},{"id":1112814,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":29667,"kind":"person","name":"MESSEMER DEBORAH M.","position":1,"cik":"0001754424","reported_name":"MESSEMER DEBORAH M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-06-12T20:18:31.000Z","date":"2025-06-10","kind":"sale","planned":true,"acquired":false,"shares":36885,"price":1.42,"value":52376.7,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 8/30/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.38 to $1.445, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":107431,"source":{"system":"sec-edgar","filing":"0001737287-25-000066","document":"wk-form4_1749759007.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000066/wk-form4_1749759007.xml","form_type":"4"}},{"id":1166976,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":51454,"kind":"person","name":"Yoshiyama Annie","position":1,"cik":"0001835208","reported_name":"Yoshiyama Annie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2025-04-23T21:28:51.000Z","date":"2025-04-21","kind":"sale","planned":false,"acquired":false,"shares":9601,"price":1.41,"value":13537.41,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 2274 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 pursuant to an employee stock purchase program."}],"balance_after":130663,"source":{"system":"sec-edgar","filing":"0001835208-25-000007","document":"wk-form4_1745443726.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000183520825000007/wk-form4_1745443726.xml","form_type":"4"}},{"id":1198656,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-03-18T21:30:50.000Z","date":"2025-03-14","kind":"sale","planned":false,"acquired":false,"shares":46668,"price":1.96,"value":91469.28,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in one transaction at a single price point of $1.96. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at the price set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 6000 shares of the Issuer's common stock acquired by the reporting person on March 14, 2025 pursuant to an employee stock purchase program."}],"balance_after":5276569,"source":{"system":"sec-edgar","filing":"0001737287-25-000042","document":"wk-form4_1742333443.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728725000042/wk-form4_1742333443.xml","form_type":"4"}},{"id":1200834,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-18T21:28:04.000Z","date":"2025-03-14","kind":"sale","planned":false,"acquired":false,"shares":5488,"price":1.975,"value":10838.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in one transaction at the single price point of $1.975. The reporting person undertakes to\nprovide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at the price  set forth above."}],"balance_after":218507,"source":{"system":"sec-edgar","filing":"0001737287-25-000040","document":"wk-form4_1742333277.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000173728725000040/wk-form4_1742333277.xml","form_type":"4"}},{"id":1223267,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Stock Option (Right to buy)","published_at":"2025-03-05T21:11:13.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":112339,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on March 1, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":112339,"derivative":{"exercise_price":1.8,"expiration_date":"2035-03-01","underlying":"Common Stock","underlying_shares":112339},"source":{"system":"sec-edgar","filing":"0001737287-25-000026","document":"wk-form4_1741209067.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000173728725000026/wk-form4_1741209067.xml","form_type":"4"}},{"id":1223266,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":54359,"kind":"person","name":"Beneski Benjamin Machinas","position":1,"cik":"0002057918","reported_name":"Beneski Benjamin Machinas","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-03-05T21:11:13.000Z","date":"2025-03-01","kind":"grant","planned":false,"acquired":true,"shares":31755,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":223995,"source":{"system":"sec-edgar","filing":"0001737287-25-000026","document":"wk-form4_1741209067.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/2057918/000173728725000026/wk-form4_1741209067.xml","form_type":"4"}},{"id":1254830,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":29667,"kind":"person","name":"MESSEMER DEBORAH M.","position":1,"cik":"0001754424","reported_name":"MESSEMER DEBORAH M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-02-20T21:15:28.000Z","date":"2025-02-18","kind":"sale","planned":true,"acquired":false,"shares":13313,"price":2.43,"value":32350.59,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 8/30/2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $2.42 to $2.44, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":144316,"source":{"system":"sec-edgar","filing":"0001737287-25-000022","document":"wk-form4_1740086122.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000022/wk-form4_1740086122.xml","form_type":"4"}},{"id":1281598,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-02-05T21:16:37.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":6404,"price":1.71,"value":10950.84,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":587848,"source":{"system":"sec-edgar","filing":"0001737287-25-000020","document":"wk-form4_1738790190.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000173728725000020/wk-form4_1738790190.xml","form_type":"4"}},{"id":1281822,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-02-05T21:15:47.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":4361,"price":1.73,"value":7544.53,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":1301540,"source":{"system":"sec-edgar","filing":"0001737287-25-000019","document":"wk-form4_1738790139.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000173728725000019/wk-form4_1738790139.xml","form_type":"4"}},{"id":1281432,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-02-05T21:13:43.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":46003,"price":1.68,"value":77285.04,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.68 to $1.69, inclusive. The reporting person undertakes to\nprovide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above."}],"balance_after":5317237,"source":{"system":"sec-edgar","filing":"0001737287-25-000017","document":"wk-form4_1738790016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728725000017/wk-form4_1738790016.xml","form_type":"4"}},{"id":1282086,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of R&D"}}],"security":"Common Stock","published_at":"2025-02-05T21:12:55.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":18832,"price":1.7,"value":32014.4,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."}],"balance_after":643135,"source":{"system":"sec-edgar","filing":"0001737287-25-000016","document":"wk-form4_1738789969.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000173728725000016/wk-form4_1738789969.xml","form_type":"4"}},{"id":1281858,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64608,"kind":"person","name":"MOORE TIMOTHY L.","position":1,"cik":"0001669207","reported_name":"MOORE TIMOTHY L.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2025-02-05T16:14:49.000Z","date":"2025-02-03","kind":"sale","planned":false,"acquired":false,"shares":14746,"price":1.71,"value":25215.66,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election\nunder its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.71 to $1.715, inclusive. The reporting person undertakes to\nprovide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above."}],"balance_after":250713,"source":{"system":"sec-edgar","filing":"0001737287-25-000018","document":"wk-form4_1738790068.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1669207/000173728725000018/wk-form4_1738790068.xml","form_type":"4"}},{"id":1292871,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-29T01:16:11.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":512370,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":512370,"derivative":{"exercise_price":1.94,"expiration_date":"2035-01-24","underlying":"Common Stock","underlying_shares":512370},"source":{"system":"sec-edgar","filing":"0001737287-25-000009","document":"wk-form4_1738113364.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000173728725000009/wk-form4_1738113364.xml","form_type":"4"}},{"id":1292870,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2025-01-29T01:16:11.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":144928,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":594252,"source":{"system":"sec-edgar","filing":"0001737287-25-000009","document":"wk-form4_1738113364.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000173728725000009/wk-form4_1738113364.xml","form_type":"4"}},{"id":1293005,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-29T01:15:11.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":614844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":614844,"derivative":{"exercise_price":1.94,"expiration_date":"2035-01-24","underlying":"Common Stock","underlying_shares":614844},"source":{"system":"sec-edgar","filing":"0001737287-25-000008","document":"wk-form4_1738113304.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000173728725000008/wk-form4_1738113304.xml","form_type":"4"}},{"id":1293004,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2025-01-29T01:15:11.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":173913,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1305901,"source":{"system":"sec-edgar","filing":"0001737287-25-000008","document":"wk-form4_1738113304.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000173728725000008/wk-form4_1738113304.xml","form_type":"4"}},{"id":1292744,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":51454,"kind":"person","name":"Yoshiyama Annie","position":1,"cik":"0001835208","reported_name":"Yoshiyama Annie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-29T01:14:07.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":128093,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":128093,"derivative":{"exercise_price":1.94,"expiration_date":"2035-01-24","underlying":"Common Stock","underlying_shares":128093},"source":{"system":"sec-edgar","filing":"0001737287-25-000007","document":"wk-form4_1738113240.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000007/wk-form4_1738113240.xml","form_type":"4"}},{"id":1292743,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":51454,"kind":"person","name":"Yoshiyama Annie","position":1,"cik":"0001835208","reported_name":"Yoshiyama Annie","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, Finance"}}],"security":"Common Stock","published_at":"2025-01-29T01:14:07.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":36232,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":137990,"source":{"system":"sec-edgar","filing":"0001737287-25-000007","document":"wk-form4_1738113240.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728725000007/wk-form4_1738113240.xml","form_type":"4"}},{"id":1293150,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of R&D"}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-29T01:13:01.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":614844,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":614844,"derivative":{"exercise_price":1.94,"expiration_date":"2035-01-24","underlying":"Common Stock","underlying_shares":614844},"source":{"system":"sec-edgar","filing":"0001737287-25-000006","document":"wk-form4_1738113175.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000173728725000006/wk-form4_1738113175.xml","form_type":"4"}},{"id":1293149,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of R&D"}}],"security":"Common Stock","published_at":"2025-01-29T01:13:01.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":173913,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":661967,"source":{"system":"sec-edgar","filing":"0001737287-25-000006","document":"wk-form4_1738113175.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000173728725000006/wk-form4_1738113175.xml","form_type":"4"}},{"id":1292933,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-29T01:11:46.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":1307927,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1307927,"derivative":{"exercise_price":1.94,"expiration_date":"2035-01-24","underlying":"Common Stock","underlying_shares":1307927},"source":{"system":"sec-edgar","filing":"0001737287-25-000005","document":"wk-form4_1738113099.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000173728725000005/wk-form4_1738113099.xml","form_type":"4"}},{"id":1292932,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-01-29T01:11:46.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":369957,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2236816,"source":{"system":"sec-edgar","filing":"0001737287-25-000005","document":"wk-form4_1738113099.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000173728725000005/wk-form4_1738113099.xml","form_type":"4"}},{"id":1292812,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to buy)","published_at":"2025-01-29T01:10:50.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":1952130,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the stock option shall vest on January 24, 2026, and the remaining shares shall vest in 36 equal monthly installments thereafter."}],"balance_after":1952130,"derivative":{"exercise_price":1.94,"expiration_date":"2035-01-24","underlying":"Common Stock","underlying_shares":1952130},"source":{"system":"sec-edgar","filing":"0001737287-25-000004","document":"wk-form4_1738113042.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728725000004/wk-form4_1738113042.xml","form_type":"4"}},{"id":1292811,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2025-01-29T01:10:50.000Z","date":"2025-01-24","kind":"grant","planned":false,"acquired":true,"shares":552174,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 960 shares of the Issuer's common stock acquired by the reporting person on September 15, 2024 pursuant to an employee stock purchase program."}],"balance_after":5363240,"source":{"system":"sec-edgar","filing":"0001737287-25-000004","document":"wk-form4_1738113042.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000173728725000004/wk-form4_1738113042.xml","form_type":"4"}},{"id":1296489,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":32172,"kind":"person","name":"Roberts Zachary","position":1,"cik":"0001851044","reported_name":"Roberts Zachary","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP of R&D"}}],"security":"Common Stock","published_at":"2025-01-23T21:30:31.000Z","date":"2025-01-21","kind":"sale","planned":false,"acquired":false,"shares":27199,"price":1.78,"value":48414.22,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in  connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plant to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.78 to $1.805, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price with in the rage set forth above."}],"balance_after":488054,"source":{"system":"sec-edgar","filing":"0001737287-25-000003","document":"wk-form4_1737667821.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1851044/000173728725000003/wk-form4_1737667821.xml","form_type":"4"}},{"id":1336720,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":29667,"kind":"person","name":"MESSEMER DEBORAH M.","position":1,"cik":"0001754424","reported_name":"MESSEMER DEBORAH M.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-10T21:53:55.000Z","date":"2024-12-09","kind":"sale","planned":true,"acquired":false,"shares":9136,"price":2.18,"value":19916.48,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices raging from $2.16 to $2.21, inclusive. The reporting person undertakes to\nprovide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price\nwithin the range set forth above."}],"balance_after":157629,"source":{"system":"sec-edgar","filing":"0001737287-24-000081","document":"wk-form4_1733867628.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000173728724000081/wk-form4_1733867628.xml","form_type":"4"}},{"id":1338673,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15984,"kind":"person","name":"Humer Franz B","position":1,"cik":"0001548072","reported_name":"Humer Franz B","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-12-09T21:05:52.000Z","date":"2024-12-05","kind":"sale","planned":false,"acquired":false,"shares":9221,"price":2.16,"value":19917.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices raging from $2.145 to $2.185, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":307507,"source":{"system":"sec-edgar","filing":"0001737287-24-000079","document":"wk-form4_1733778343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1548072/000173728724000079/wk-form4_1733778343.xml","form_type":"4"}},{"id":1382359,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-10-23T20:21:32.000Z","date":"2024-10-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":36404,"price":2.84,"value":103387.36,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.82 to $2.87, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 3,974 shares of the Issuer's common stock acquired by the reporting person on September 15, 2024 pursuant to an employee stock purchase program."}],"balance_after":1131988,"source":{"system":"sec-edgar","filing":"0001737287-24-000065","document":"wk-form4_1729714884.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000173728724000065/wk-form4_1729714884.xml","form_type":"4"}},{"id":1424068,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2024-08-23T20:15:09.000Z","date":"2024-08-21","kind":"tax_withholding","planned":false,"acquired":false,"shares":28310,"price":2.785,"value":78843.35,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.75 to $2.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":449324,"source":{"system":"sec-edgar","filing":"0001593968-24-001096","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000159396824001096/primary_01.xml","form_type":"4"}},{"id":1472723,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":29667,"kind":"person","name":"MESSEMER DEBORAH M.","position":1,"cik":"0001754424","reported_name":"MESSEMER DEBORAH M.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-20T20:31:35.000Z","date":"2024-06-18","kind":"sale","planned":true,"acquired":false,"shares":18641,"price":2.2793,"value":42488.4313,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 06/29/2023"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25 to $2.30, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":166765,"source":{"system":"sec-edgar","filing":"0001593968-24-000878","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000159396824000878/primary_01.xml","form_type":"4"}},{"id":1486045,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":10744,"kind":"person","name":"Mayo Stephen","position":1,"cik":"0001849061","reported_name":"Mayo Stephen","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-07T21:35:52.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":191082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":191082,"derivative":{"exercise_price":2.44,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":191082},"source":{"system":"sec-edgar","filing":"0001593968-24-000841","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000159396824000841/primary_01.xml","form_type":"4"}},{"id":1486044,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35887,"kind":"person","name":"Barrett Elizabeth A.","position":1,"cik":"0001764157","reported_name":"Barrett Elizabeth A.","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-07T21:34:50.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":191082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":191082,"derivative":{"exercise_price":2.44,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":191082},"source":{"system":"sec-edgar","filing":"0001593968-24-000840","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000159396824000840/primary_01.xml","form_type":"4"}},{"id":1486395,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-07T21:33:48.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":95541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":95541,"derivative":{"exercise_price":2.44,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":95541},"source":{"system":"sec-edgar","filing":"0001593968-24-000839","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000159396824000839/primary_01.xml","form_type":"4"}},{"id":1486394,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15710,"kind":"person","name":"SATO VICKI L","position":1,"cik":"0001197020","reported_name":"SATO VICKI L","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-07T21:33:48.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":61475,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":162575,"source":{"system":"sec-edgar","filing":"0001593968-24-000839","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1197020/000159396824000839/primary_01.xml","form_type":"4"}},{"id":1486199,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15984,"kind":"person","name":"Humer Franz B","position":1,"cik":"0001548072","reported_name":"Humer Franz B","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-07T21:30:46.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":95541,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":95541,"derivative":{"exercise_price":2.44,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":95541},"source":{"system":"sec-edgar","filing":"0001593968-24-000838","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1548072/000159396824000838/primary_01.xml","form_type":"4"}},{"id":1486198,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15984,"kind":"person","name":"Humer Franz B","position":1,"cik":"0001548072","reported_name":"Humer Franz B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-07T21:30:46.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":61475,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":316728,"source":{"system":"sec-edgar","filing":"0001593968-24-000838","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1548072/000159396824000838/primary_01.xml","form_type":"4"}},{"id":1486055,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35889,"kind":"person","name":"WITTE OWEN N.","position":1,"cik":"0001700969","reported_name":"WITTE OWEN N.","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-07T21:29:44.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":191082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":191082,"derivative":{"exercise_price":2.44,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":191082},"source":{"system":"sec-edgar","filing":"0001593968-24-000837","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1700969/000159396824000837/primary_01.xml","form_type":"4"}},{"id":1486414,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35936,"kind":"person","name":"Kazam Joshua A","position":1,"cik":"0001221355","reported_name":"Kazam Joshua A","relationship":{"director":true}}],"security":"Stock Option (Right to buy)","published_at":"2024-06-07T21:28:42.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":191082,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Vesting in 12 equal monthly installments"}],"balance_after":191082,"derivative":{"exercise_price":2.44,"expiration_date":"2034-06-05","underlying":"Common Stock","underlying_shares":191082},"source":{"system":"sec-edgar","filing":"0001593968-24-000836","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1221355/000159396824000836/primary_01.xml","form_type":"4"}},{"id":1486043,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":29667,"kind":"person","name":"MESSEMER DEBORAH M.","position":1,"cik":"0001754424","reported_name":"MESSEMER DEBORAH M.","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-07T21:25:40.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":122950,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":185406,"source":{"system":"sec-edgar","filing":"0001593968-24-000835","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1737287/000159396824000835/primary_01.xml","form_type":"4"}},{"id":1494830,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":15984,"kind":"person","name":"Humer Franz B","position":1,"cik":"0001548072","reported_name":"Humer Franz B","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-06-03T20:09:09.000Z","date":"2024-05-30","kind":"sale","planned":false,"acquired":false,"shares":11200,"price":2.3376,"value":26181.12,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.31 to $2.37, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":255253,"source":{"system":"sec-edgar","filing":"0001593968-24-000783","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1548072/000159396824000783/primary_01.xml","form_type":"4"}},{"id":1508828,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T01:33:32.000Z","date":"2024-05-16","kind":"purchase","planned":false,"acquired":true,"shares":1724137,"price":2.9,"value":4999997.3,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Consists of 1,720,172 shares of common stock acquired by Vida Ventures III, L.P. and 3,965 shares of common stock acquired by Vida Ventures III A, L.P. from Goldman Sachs (the Underwriter) in a registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"The securities are held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. Vida Ventures GP III, LLC is the manager of Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person is a Senior Managing Director of Vida Ventures GP III, LLC and may therefore be deemed to be the beneficial owner of the common shares held by Vida Ventures III, L.P. and Vida Ventures III-A, L.P. The reporting person disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein."}],"balance_after":1724137,"source":{"system":"sec-edgar","filing":"0001737287-24-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000173728724000042/primary_doc.xml","form_type":"4"}},{"id":1508827,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":35650,"kind":"person","name":"Belldegrun Arie","position":1,"cik":"0001296549","reported_name":"Belldegrun Arie","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-21T01:33:32.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":344828,"price":2.9,"value":1000001.2,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the \"Issuer\") in a registered direct offering."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"The securities are held in the name of Bellco Legacy LLC. Bellco Legacy LLC is owned and managed by trusts controlled by the reporting person and Rebecka Belldegrun."}],"balance_after":539867,"source":{"system":"sec-edgar","filing":"0001737287-24-000042","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1296549/000173728724000042/primary_doc.xml","form_type":"4"}},{"id":1508936,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"officer":true,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-05-20T22:02:28.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":344828,"price":2.9,"value":1000001.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the \"Issuer\") in a registered direct offering."}],"balance_after":1164418,"source":{"system":"sec-edgar","filing":"0001593968-24-000715","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000159396824000715/primary_01.xml","form_type":"4"}},{"id":1508547,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-05-20T22:01:27.000Z","date":"2024-05-16","kind":"grant","planned":false,"acquired":true,"shares":344828,"price":2.9,"value":1000001.2,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These shares of common stock were acquired directly from Allogene Therapeutics, Inc (the \"Issuer\") in a registered direct offering."}],"balance_after":4810106,"source":{"system":"sec-edgar","filing":"0001593968-24-000714","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000159396824000714/primary_01.xml","form_type":"4"}},{"id":1536210,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":64608,"kind":"person","name":"MOORE TIMOTHY L.","position":1,"cik":"0001669207","reported_name":"MOORE TIMOTHY L.","relationship":{"officer":true,"officer_title":"Chief Technical Officer"}}],"security":"Common Stock","published_at":"2024-04-24T16:18:41.000Z","date":"2024-04-22","kind":"tax_withholding","planned":false,"acquired":false,"shares":17360,"price":3.4671,"value":60188.856,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.44 to $3.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."}],"balance_after":265459,"source":{"system":"sec-edgar","filing":"0001593968-24-000614","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1669207/000159396824000614/primary_01.xml","form_type":"4"}},{"id":1571920,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":58077,"kind":"person","name":"Chang David D","position":1,"cik":"0001611024","reported_name":"Chang David D","relationship":{"director":true,"officer":true,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-19T00:10:36.000Z","date":"2024-03-14","kind":"tax_withholding","planned":false,"acquired":false,"shares":53393,"price":4.33,"value":231191.69,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a \"sell to cover\" transaction and does not represent a discretionary trade by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.29 to $4.43, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 5,468 shares of the Issuer's common stock acquired by the reporting person on March 15, 2024 pursuant to an employee stock purchase program."}],"balance_after":4465278,"source":{"system":"sec-edgar","filing":"0001593968-24-000477","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1611024/000159396824000477/primary_01.xml","form_type":"4"}},{"id":1591590,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"officer":true,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-03-07T02:52:06.000Z","date":"2024-01-30","kind":"purchase","planned":false,"acquired":true,"shares":190,"price":3.595,"value":683.05,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Mr. Parker was notified by his broker on March 4, 2024 that these shares were purchased in an account held by the Geoffrey M. Parker and Jill G. Parker Rev. Trust dated January 27, 2000 for which Mr. Parker does not have discretion.  This account is intended to closely track the performance of the Russell 2000 and is frequently rebalanced by an algorithm designed by the broker which led to the purchase of these shares.  Restrictions have been now placed on all such accounts held by the Trust to avoid such purchases of the Issuer stock in the future."}],"balance_after":819590,"source":{"system":"sec-edgar","filing":"0001593968-24-000449","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000159396824000449/primary_01.xml","form_type":"4"}},{"id":1664927,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-31T22:48:49.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":147778,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter."}],"balance_after":147778,"derivative":{"exercise_price":3.2,"expiration_date":"2034-01-25","underlying":"Common Stock","underlying_shares":147778},"source":{"system":"sec-edgar","filing":"0001593968-24-000196","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000159396824000196/primary_01.xml","form_type":"4"}},{"id":1664926,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":19834,"kind":"person","name":"Douglas Earl Martin","position":1,"cik":"0001362155","reported_name":"Douglas Earl Martin","relationship":{"officer":true,"officer_title":"SVP, General Counsel"}}],"security":"Common Stock","published_at":"2024-01-31T22:48:49.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":41800,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":477634,"source":{"system":"sec-edgar","filing":"0001593968-24-000196","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1362155/000159396824000196/primary_01.xml","form_type":"4"}},{"id":1665120,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"officer":true,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-31T22:47:41.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":103939,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/3 of the shares subject to the stock option shall vest on January 25, 2025, and the remaining shares shall vest in 24 equal monthly installments thereafter."}],"balance_after":103939,"derivative":{"exercise_price":3.2,"expiration_date":"2034-01-25","underlying":"Common Stock","underlying_shares":103939},"source":{"system":"sec-edgar","filing":"0001593968-24-000195","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000159396824000195/primary_01.xml","form_type":"4"}},{"id":1665119,"issuer":{"id":5243,"kind":"organization","name":"Allogene Therapeutics, Inc."},"owners":[{"id":37676,"kind":"person","name":"Parker Geoffrey M.","position":1,"cik":"0001491874","reported_name":"Parker Geoffrey M.","relationship":{"officer":true,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Common Stock","published_at":"2024-01-31T22:47:41.000Z","date":"2024-01-25","kind":"grant","planned":false,"acquired":true,"shares":29400,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":819400,"source":{"system":"sec-edgar","filing":"0001593968-24-000195","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1491874/000159396824000195/primary_01.xml","form_type":"4"}}],"next_cursor":"2024-01-31T22:47:41.000000Z,1665119"}